News | Prostate Cancer | November 02, 2015

First Results Reported for Prostate Cancer Targeted Brachytherapy Using CivaString

Palladium-based source offers positive outcomes with more highly targeted radiation

CivaTech Oncology, CivaString, prostate brachytherapy, 103Pd radiation source, ASTRO 2015

Image courtesy of Business Wire

November 2, 2015 — CivaTech Oncology Inc. has developed a new U.S. Food and Drug Administration (FDA)-cleared radiation source. The CivaString source features 103Pd (palladium) along the full length of the device, which is contained using low-Z polymers. Low-dose-rate brachytherapy historically relies on a loose or stranded isotope whose dosimetry is characterized as point sources. A polymer-encapsulated 103Pd source with a unique linear radioactive distribution provides a useful refinement for prostate brachytherapy.

An abstract and poster titled “First Report of a New 103Pd Line Source for Prostate Brachytherapy” presenting results from the first 14 patients in an ongoing clinical study was submitted and accepted at the American Society for Radiation Oncology (ASTRO) 2015 conference in San Antonio, and published in ASTRO’s International Journal of Radiation Oncology. Radiation oncologists David Beyer, M.D., and Richard Stock, M.D., implanted patients in Arizona and New York.

The abstract concluded: “An initial experience with this new line source is presented. Excellent implants across a range of gland sizes were accomplished. Prostate volume changes were minimal suggesting minimal swelling using the chosen needles and ‘strings.’ Good dosimetry is achieved for both preplans and eventual implants. Using a line source, the number of needles required per patient is less than that reported with standard brachytherapy sources. Intraoperative ease of use is good.”

This study is ongoing with 26 total patients and is expected to conclude at the end of 2015, at which time a full report will be published. Additionally a five-year, 150-patient registry has begun to fully demonstrate how the advanced polymer technology benefits patients when used to treat prostate cancer.

For more information:

Related Content

Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

Getty Images

News | Prostate Cancer | September 24, 2021
September 24, 2021 — Scientists have identified two subtypes of metastatic...
The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s Fixed), By Application (Breast Cancer, Head & Neck Cancer, Abdominal & Pelvic Cancer, Dermatology, Others), By End User, By Region, Competition Forecast & Opportunities, 2026" report

Image courtesy of Varian

News | Radiation Therapy | September 24, 2021
September 24, 2021 — The ...
The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center and City of Hope Comprehensive Cancer Center secured a highly competitive Specialized Program of Research Excellence (SPORE) grant that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs and community outreach.

VCU Massey Cancer Center director and SPORE principal investigator Dr. Robert Winn explains how this grant will help combat racial inequities in lung cancer. Image courtesy of VCU Massey Cancer Center

News | Lung Imaging | September 23, 2021
September 23, 2021 — The National Cancer Institute announced tha
Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.
News | Digital Pathology | September 22, 2021
September 22, 2021 — The U.S.
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...